Compare Global X FTSE Southeast Asia ETF (ASEA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Tempus AI — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Tempus AI trades at $57.49 (market cap $10.46B). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| ASEA | TEM | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $20.65 | $103.25 |
52-Week Low | $16.31 | $42.37 |
Market Cap | — | $10.46B |
Enterprise Value | — | $11.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Tempus AI (TEM) trades at $58.23, down 5.26% for the day, as the precision medicine technology company continues to show strong revenue growth but significant losses. The stock maintains a bullish technical signal with support at $58 and resistance at $64, while analysts remain optimistic with 61.5% buy ratings and a $63.50 consensus target. Recent FDA approvals for diagnostic tests and expanding AI platform capabilities provide growth catalysts despite ongoing operational losses.
The investment case hinges on Tempus's unique healthcare data platform and AI capabilities driving long-term growth, though substantial GAAP losses and negative cash flow from operations present near-term execution risks. With revenue projected to reach $1.4B in 2026 but net losses widening to $303M, the stock offers asymmetric upside if the company can achieve profitability while maintaining its 25%+ growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
